Analysis of Urinary Stone Composition: A Retrospective Single Center Study during the Last Five Years (2009-2013)

Pil Moon Kang; Won Ik Seo; Dong Il Kang

doi:10.14777/kjutii.2014.9.1.44

Journal List > Korean J Urogenit Tract Infect Inflamm > v.9(1) > 1059948

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kang, Seo, and Kang: Analysis of Urinary Stone Composition: A Retrospective Single Center Study during the Last Five Years (2009-2013)

Original Article

Korean J Urogenit Tract Infect Inflamm 2014;9(1):44-49.

Published online: 17 April 2014

DOI: https://doi.org/10.14777/kjutii.2014.9.1.44

Analysis of Urinary Stone Composition: A Retrospective Single Center Study during the Last Five Years (2009-2013)

Pil Moon Kang, Won Ik Seo, Dong Il Kang

Department of Urology, Inje University College of Medicine, Busan, Korea

Correspondence to: Dong Il Kang Department of Urology, Inje University Busan Paik Hospital, 75, Bokji-ro, Busanjin-gu, Busan 614-735, Korea Tel: +82-51-890-6439, Fax: +82-51-892-9887 E-mail: urokang@lycos.co.kr

Received 14 February 201424 March 2014 Accepted 27 March 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

Analysis of urinary stone composition is essential for treatment and prevention of urolithiasis. We evaluated the effect of age, gender, and stone location on urinary stone components during the last five years.

Materials and Methods

We conducted a retrospective analysis of the medical records of 375 patients ranging in age from 15 years old to 93 years old (241 males and 134 females) who underwent conventional or endoscopic surgery, shock wave lithotripsy, or passed their stones spontaneously between 2009 and 2013. Stone analysis was performed using a chemical analysis method to determine the molecular composition of each stone.

Results

Of the 375 patients with urolithiasis, 152 patients (40.5%) had predominantly calcium oxalate, 85 patients (21.5%) had uric acid, 17 patients (4.5%) had calcium phosphate, 17 patients (4.5%) had magnesium ammonium phosphate, 16 patients (4.3%) had calcium carbonate, and 86 patients (22.9%) had mixed stone type. There was a decreasing prevalence of calcium oxalate stone with age group (42.5% in young adult (20-39 years, n=40), 45.0% in adult (40-60 years, n=151), and 32.7% in elderly (≥60 years, n=180) as opposed to increasing prevalence in uric acid stone (7.5% in young adult, 15.2% in adult and 32.2% in elderly). Uric acid stones were more common in males and in lower urinary tract stones.

Conclusions

In this study, the incidence of calcium oxalate decreased with age and that of uric acid increased with age and in male. In comparison of the results of previous studies for several decades, the incidence of uric acid increased in the last five years.

Go to :

Keywords: Urinary calculi, Analysis, Uric acid

REFERENCES

1. Saita A, Bonaccorsi A, Motta M. Stone composition: where do we stand? Urol Int. 2007; 79(Suppl 1):16–9.

2. Kim Hh. Jo MK, Kwak C, Park SK, Yoo KY, Kang D, et al. Prevalence and epidemiologic characteristics of urolithiasis in Seoul, Korea. Urology. 2002; 59:517–21.

3. Johnson CM, Wilson DM, O'Fallon WM, Malek RS, Kurland LT. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int. 1979; 16:624–31.

4. Smith LH. The medical aspects of urolithiasis: an overview. J Urol. 1989; 141:707–10.

5. Alaya A, Nouri A, Belgith M, Saad H, Jouini R, Najjar MF. Changes in urinary stone composition in the Tunisian population: a retrospective study of 1,301 cases. Ann Lab Med. 2012; 32:177–83.

6. Goldfarb DS, Coe FL. Prevention of recurrent nephrolithiasis. Am Fam Physician. 1999; 60:2269–76.

7. Kourambas J, Aslan P, Teh CL, Mathias BJ, Preminger GM. Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. J Endourol. 2001; 15:181–6.

8. Basiri A, Taheri M, Taheri F. What is the state of the stone analysis techniques in urolithiasis? Urol J. 2012; 9:445–54.

9. Asper R. Epidemiology and socioeconomic aspects of urolithiasis. Urol Res. 1984; 12:1–5.

10. Hesse A, Siener R. Current aspects of epidemiology and nutrition in urinary stone disease. World J Urol. 1997; 15:165–71.

11. Daudon M, Donsimoni R, Hennequin C, Fellahi S, Le Moel G, Paris M, et al. Sex- and age-related composition of 10 617 calculi analyzed by infrared spectroscopy. Urol Res. 1995; 23:319–26.

12. Byeon SS, Kim HH, Kim SW. Analysis of the urinary stone components using chemical analysis method. Korean J Urol. 1996; 37:179–86.

13. Ye SJ, Yoo ES, Park YK. Analysis of urinary stone components during the last two decades. Korean J Urol. 2007; 48:1285–88.

14. Balaji KC, Menon M. Mechanism of stone formation. Urol Clin North Am. 1997; 24:1–11.

15. Menon M, Mahle CJ. Oxalate metabolism and renal calculi. J Urol. 1982; 127:148–51.

16. Finlayson B. Symposium on renal lithiasis. Renal lithiasis in review. Urol Clin North Am. 1974; 1:181–212.

17. Siener R, Glatz S, Nicolay C, Hesse A. The role of overweight and obesity in calcium oxalate stone formation. Obes Res. 2004; 12:106–13.

18. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005; 115:2598–608.

19. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004; 65:386–92.

20. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004; 65:1422–5.

21. Negri AL, Spivacow R, Del Valle E, Pinduli I, Marino A, Fradinger E, et al. Clinical and biochemical profile of patients with "pure" uric acid nephrolithiasis compared with "pure" calcium oxalate stone formers. Urol Res. 2007; 35:247–51.

22. Zechner O, Pfluger H, Scheiber V. Idiopathic uric acid lithiasis: epidemiologic and metabolic aspects. J Urol. 1982; 128:1219–23.

23. Poletto J, Harima HA, Ferreira SR, Gimeno SG. Hyperuricemia and associated factors: a cross-sectional study of Japanese-Brazilians. Cad Saude Publica. 2011; 27:369–78.

24. Childs MA, Mynderse LA, Rangel LJ, Wilson TM, Lingeman JE, Krambeck AE. Pathogenesis of bladder calculi in the presence of urinary stasis. J Urol. 2013; 189:1347–51.

Go to :

Table 1.

Components of 375 urinary calculi and distribution according to the gender

Stone component	Patients	Gender
Stone component	Patients	Male	Female
Pure (n=289)
CaOx	152 (40.5)	94 (39.0)	58 (43.2)
UA	85 (21.5)	69 (28.6)	16 (11.9)
CaP	17 (4.5)	13 (5.3)	4 (2.9)
MAP	17 (4.5)	9 (3.7)	8 (5.9)
AAU	0	0	0
Cystine	2 (0.5)	2 (0.8)	0
CaCarb	16 (4.3)	4 (1.7)	12 (8.9)
Mixed (n=86)
CaOx+UA	23 (6.1)	19 (7.9)	4 (2.9)
CaOx+CaP	6 (1.6)	3 (1.2)	3 (2.2)
CaOx+MAP	1 (0.3)	0	1 (0.7)
CaOx+CaCarb	14 (3.7)	8 (3.3)	6 (4.5)
UA+CaP	2 (0.5)	2 (0.8)	0
UA+MAP	4 (1.1)	4 (1.7)	0
UA+Cystine	1 (0.3)	0	1 (0.7)
UA+CaCarb	1 (0.3)	0	1 (0.7)
CaP+Cystine	1 (0.3)	0	1 (0.7)
CaP+CaCarb	13 (3.5)	4 (11.7)	9 (6.7)
MAP+CaCarb	7 (1.9)	3 (1.2)	4 (3.0)
CaOx+UA+CaCarb	2 (0.5)	2 (0.8)	0
CaOx+CaP+CaCarb	11 (2.9)	5 (2.0)	6 (4.5)
Total	375	241	134

Values are presented as number (%). CaOx: calcium oxalate, UA: uric acid, CaP: calcium phosphate, MAP: magnesium ammonium phosphate, AAU: ammonium acid, CaCarb: calcium carbonate.

Table 2.

Distribution of urinary stone according to the age

Stone component	Age
Stone component	Child	Young	Adult	Elderly
Pure
CaOx	3 (75.0)	17 (42.5)	68 (45.0)	59 (32.7)
UA		3 (7.5)	23 (15.2)	58 (32.2)
CaP	1 (25.0)	6 (15)	6 (3.9)	3 (1.6)
MAP	-	2 (5)	4 (2.6)	11 (6.1)
AAU	-	-	-	-
Cystine	-	2 (5)	-	-
CaCarb	-	2 (5)	8 (5.2)	9 (5.0)
Mixed
CaOx+UA	-	1 (2.5)	9 (5.9)	13 (7.2)
CaOx+CaP	-	-	8 (5.2)	3 (1.7)
CaOx+MAP	-	-	4 (2.6)	-
CaOx+CaCarb	-	1 (2.5)	7 (4.6)	6 (3.3)
UA+CaP	-	1 (2.5)	-	1 (0.6)
UA+MAP	-	-	2 (1.3)	3 (1.7)
UA+Cystine	-	1 (2.5)	-	-
UA+CaCarb	-	1 (2.5)	-	1
CaP+Cystine	-	1 (2.5)	-	-
CaP+CaCarb	-	1 (2.5)	5 (3.3)	8
MAP+CaCarb	-	-	-	2
CaOx+UA+CaCarb	-	-	-	-
CaOx+CaP+CaCarb	-	-	-	-
Total	4	40	151	180

Values are presented as number (%). Child (0-19 years), young (20-39 years), adult (40-59 years), elderly (over 60 years). CaOx: calcium oxalate, UA: uric acid, CaP: calcium phosphate, MAP:magnesium ammonium phosphate, AAU: ammonium acid, CaCarb:calcium carbonate.

Table 3.

Distribution of urinary stone according to the location

Stone component	Location
Stone component	Kidney	Ureter	Bladder	Urethra
Pure
CaOx	41 (35.6)	93 (50.5)	17 (24.2)	2 (33.3)
UA	21 (18.2)	41 (22.2)	22 (31.4)	1 (16.7)
CaP	5 (4.3)	7 (3.8)	2 (2.8)	1 (16.7)
MAP	8 (6.9)	2 (1.0)	7 (10.0)	-
AAU	-	-	-	-
Cystine	2 (1.7)	-	-	-
CaCarb	8 (6.9)	7 (3.8)	1 (1.4)	-
Mixed
CaOx+UA	10 (8.7)	6 (3.3)	6 (8.6)	-
CaOx+CaP	-	5 (2.7)	1 (1.4)	-
CaOx+MAP	-	-	1 (1.4)	-
CaOx+CaCarb	6 (5.2)	5 (2.7)	4 (5.7)	1 (16.7)
UA+CaP	1 (0.9)	1 (0.5)	-	-
UA+MAP	1 (0.9)	-	3 (4.3)	-
UA+Cystine	-	1 (0.5)	-	-
UA+CaCarb	-	2 (1.1)	-	-
UA+CaCarb CaP+Cystine	- 1 (0.9)	2 (1.1) -	- -	- -
CaP+CaCarb	3 (2.6)	5 (2.7)	3 (4.3)	1 (16.7)
MAP+CaCarb	5 (4.3)	-	2 (2.9)	-
CaOx+UA+CaCarb	1 (0.9)	1 (0.5)	-	-
CaOx+CaP+CaCarb	2 (1.7)	8 (4.3)	1 (1.4)	-
Total	115	184	70	6

Values are presented as number (%). CaOx: calcium oxalate, UA: uric acid, CaP: calcium phosphate, MAP: magnesium ammonium phosphate, AAU: ammonium acid, CaCarb: calcium carbonate.

Table 4.

Compairing data - current and previous periods

	Kang et al. (present case)	Byeon et al.¹²	Ye et al.¹³
	Kang et al. (present case)	Byeon et al.¹²	A	B
Duration (y)	2009-2013	1985-1995	1986-1995	1996-2005
Case (n)	375	495	301	158
Age (y)	2-93 (57.6±14.4)	2-76 (49.5±12.5)	47.2±14.5	46.0±10.2
Sex ratio (male:female)	1.8:1	1.8:1	2.04:1	1.98:1
Location	-	-	-	-
Kidney	115	307	110	61
Ureter	184	103	166	81
Bladder	70	75	15	10
Urethra	6	10	10	6
Stone analysis method	Chemical analysis	Chemical analysis	Louis C. Herring and Company
Stone component
Pure	-	-	-	-
CaOx	152 (40.5)	173 (46.3)	30 (10.0)	12 (7.6)
UA	85 (21.5)	18 (3.6)	17 (5.6)	24 (15.2)
CaP	17 (4.5)	23 (4.6)	5 (1.7)	7 (4.4)
MAP AAU	17 (4.5) -	15 (3.0) -	- -	- -
Cystine	2 (0.5)	-	1 (0.3)	1 (0.6)
CaCarb	16 (4.3)	-	-	-
Mixed
CaOx+UA	23 (6.1)	16 (3.2)	18 (6.0)	10 (6.3)
CaOx+CaP CaOx+MAP	6 (1.6) 1 (0.3)	118 (23.8) 17 (3.4)	182 (60.5) 3 (1.0)	80 (50.6) 1 (0.6)
CaOx+CaCarb	14 (3.7)	-	-	-
CaOx+AAU	-	-	2 (0.7)	-
UA+CaP	2 (0.5)	6 (1.2)	-	-
UA+MAP	4 (1.1)	3 (0.6)	-	-
UA+Cystine UA+CaCarb	1 (0.3) 1 (0.3)	- -	- -	- -
UA+AAU	-	-	-	2 (1.3)
CaP+Cystine	1 (0.3)	-	-	-
CaP+CaCarb	13 (3.5)	-	-	-
CaP+MAP	-	-	5 (1.7)	9 (5.7)
MAP+CaCarb CaOx+Cystine	7 (1.9) -	- 1 (0.2)	- -	- -
CaP+MAP	-	20 (4.0)	-	-
CaOx+UA+CaCarb	2 (0.5)	-	-	-
CaOx+CaP+CaCarb	11 (2.9)	-	-	-
CaOx+CaP+MAP	-	71 (14.3)	14 (4.7)	4 (2.5)
CaOx+MAP+UA CaOx+CaP+UA	- -	1 (0.2) 7 (1.4)	- 9 (3.0)	- -
CaOx+CaP+Cys	-	1 (0.2)	-	-
CaOx+UA+ AAU	-	-	1 (0.3)	1 (0.6)
CaOx+CaP+AAU	-	-	2 (0.7)	-
CaP+MAP+UA	-	5 (1.0)	-	-
CaP+MAP+AAU CaOx+CaP+MAP+AAU	- -	- -	7 (2.3) 1 (0.3)	4 (2.5) 1 (0.6)
CaOx+CaP+UA+AAU	-	-	3 (1.0)	2 (1.3)
CaOx+CaP+UA+MAP+AAU	-	-	1 (0.3)	-

Values are presented as number (%), range (mean±standard deviation) or mean±standard deviation only.CaOx: calcium oxalate, UA: uric acid, CaP: calcium phosphate, MAP: magnesium ammonium phosphate, AAU: ammonium acid, CaCarb: calcium carbonate.

TOOLS

Similar articles